 Product Surveillance, Postmarketing
"Product Surveillance, Postmarketing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Surveillance of drugs, devices, appliances, etc., for efficacy or adverse effects, after they have been released for general sale.
| Descriptor ID |
D011358
|
| MeSH Number(s) |
E05.337.800
|
| Concept/Terms |
Product Surveillance, Postmarketing- Product Surveillance, Postmarketing
- Product Surveillance, Post-Marketing
- Post-Marketing Product Surveillance
- Post-Marketing Product Surveillances
- Product Surveillance, Post Marketing
- Product Surveillances, Post-Marketing
- Surveillance, Post-Marketing Product
- Surveillances, Post-Marketing Product
- Evaluation Studies, Postmarketing
- Evaluation Study, Postmarketing
- Postmarketing Evaluation Studies
- Postmarketing Evaluation Study
- Studies, Postmarketing Evaluation
- Study, Postmarketing Evaluation
- Postmarketing Product Surveillance
- Postmarketing Product Surveillances
- Product Surveillances, Postmarketing
- Surveillance, Postmarketing Product
- Surveillances, Postmarketing Product
Drug Surveillance, Postmarketing- Drug Surveillance, Postmarketing
- Drug Surveillances, Postmarketing
- Postmarketing Drug Surveillance
- Postmarketing Drug Surveillances
- Surveillance, Postmarketing Drug
- Surveillances, Postmarketing Drug
|
Below are MeSH descriptors whose meaning is more general than "Product Surveillance, Postmarketing".
Below are MeSH descriptors whose meaning is more specific than "Product Surveillance, Postmarketing".
This graph shows the total number of publications written about "Product Surveillance, Postmarketing" by people in this website by year, and whether "Product Surveillance, Postmarketing" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 | | 2004 | 1 | 1 | 2 | | 2005 | 0 | 1 | 1 | | 2006 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 3 | 0 | 3 | | 2012 | 3 | 2 | 5 | | 2013 | 5 | 4 | 9 | | 2014 | 1 | 1 | 2 | | 2015 | 3 | 3 | 6 | | 2016 | 1 | 0 | 1 | | 2017 | 1 | 2 | 3 | | 2018 | 2 | 0 | 2 | | 2019 | 3 | 2 | 5 | | 2020 | 1 | 2 | 3 | | 2022 | 0 | 1 | 1 | | 2024 | 1 | 1 | 2 | | 2025 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Product Surveillance, Postmarketing" by people in Profiles.
-
Donahue JG, Cocoros NM, Kieke BA, Hanson KE, Weintraub ES, Yih WK, Scotty E, McClure DL, Fireman B, Boyce TG, Maro JC, Bartlett J, Glanz JM, Haapala JL, Horberg M, Hurley L, Irving SA, Jackson LA, Kim S, Klein NP, McNeil MM, Myers TR, Qian L, Smith N, Sundaram ME, Tartof S, Wang L, Xu S, Belongia EA. Near real-time surveillance and tree-based data mining to assess the safety of respiratory syncytial virus vaccines in older adults in the vaccine safety datalink. Vaccine. 2025 Nov 20; 67:127873.
-
Hills SL, Sutter RA, Miller ER, Asturias EJ, Chen LH, Bell BP, McNeil MM, Rakickas J, Wharton M, Meyer S, Staples JE. Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025. Euro Surveill. 2025 Aug; 30(32).
-
Almasri H, Karna R, Sidhu G, Khataniar H, Bassett J, Bilal M. Analysis of Reported Adverse Events Associated with Sphincterotomes: An FDA Manufacturer and User Facility Device Experience (MAUDE) Database Study. Dig Dis Sci. 2025 Oct; 70(10):3552-3562.
-
Greenberg BM, Fujihara K, Weinshenker B, Patti F, Kleiter I, Bennett JL, Palace J, Blondeau K, Burdeska A, Ngwa I, Klingelschmitt G, Triyatni M, Yamamura T. Analysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims data. Mult Scler Relat Disord. 2025 Jul; 99:106444.
-
Mahadevan U, Levy G, Gensler L, Ali M, Lacerda AP, Wegrzyn L, Palac H, Bhutani-Jacques T, Long M, Clowse MEB, Kimball AB, Chambers C, Scialli AR. Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing Reports. Drug Saf. 2024 Oct; 47(10):1039-1049.
-
Adams C, Keller M, Michlitsch JG, Aguayo-Hiraldo P, Chen K, Hossain MZ, Davis A, Park JR, Verneris MR, Gardner RA. Development of a Safety Surveillance Plan for the Academic Medicine Sponsor Performing First-in-Human Cellular Therapy Clinical Trials: A Report from the Consortium for Pediatric Cellular Immunotherapy. Transplant Cell Ther. 2024 05; 30(5):475-487.
-
Duffy J, Marquez P, Moro P, Weintraub E, Yu Y, Boersma P, Donahue JG, Glanz JM, Goddard K, Hambidge SJ, Lewin B, Lewis N, Rouse D, Shimabukuro T. Safety Monitoring of JYNNEOS Vaccine During the 2022 Mpox Outbreak - United States, May 22-October 21, 2022. MMWR Morb Mortal Wkly Rep. 2022 Dec 09; 71(49):1555-1559.
-
Bernhardt MB, Lindsay H, Allen-Rhoades W, Foster JH. The Best Pharmaceuticals for Children Act and Pediatric Research Equity Act reach the age of majority-An oncology perspective. Pediatr Blood Cancer. 2021 03; 68(3):e28871.
-
Asgari MM, Tsai AL, Avalos L, Sokil M, Quesenberry CP. Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis. JAMA Dermatol. 2020 10 01; 156(10):1066-1073.
-
Rathi VK, Krumholz HM, Masoudi FA, Ross JS. Postmarket Clinical Evidence for High-Risk Therapeutic Medical Devices Receiving Food and Drug Administration Premarket Approval in 2010 and 2011. JAMA Netw Open. 2020 08 03; 3(8):e2014496.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|